Anti-carcinogenic effects of sulforaphane in association with its apoptosis-inducing and anti-inflammatory properties in human cervical cancer cells

Cancer Epidemiology

Volumn 35, Issue 3, 2011, Pages 272-278

  Sharma, Chhavi ^a   Sadrieh, Lida ^a   Priyani, Anita ^a   Ahmed, Musthaq ^a   Hassan, Ahmad H ^b   Hussain, Arif ^a  

^a Manipal University   (United Arab Emirates)

^b UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Bcl 2; Chemoprevention; COX 2; Gemcitabine; IL 1 ; Sulforaphane

Indexed keywords

CYCLOOXYGENASE 2; GEMCITABINE; INTERLEUKIN 1BETA; PROTEIN BCL 2; SULFORAPHANE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL ASSAY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE CERVIX CANCER;

ANTICARCINOGENIC AGENTS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL SURVIVAL; CYCLOOXYGENASE 2; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIOCYANATES; UTERINE CERVICAL NEOPLASMS;

EID: 79956040609     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2010.09.008     Document Type: Article

References (73)

1. Holmes K., Egan B., Swan N., Morain C.O. Genetic mechanisms and aberrant gene expression during the development of gastric intestinal metaplasia and adenocarcinoma. Curr Genomics 2007, 8(6):379-397.
2. Aapro M.S., Martin C., Hatty S. Review paper: gemcitabine - a safety review. Anti-Cancer Drugs 1998, 9:191-201.
3. Abratt R.P., Bezwoda W.R., Falkson G., Goedhals L., Hacking D., Rugg T.A. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994, 12:1535-1540.
4. Tsao A.S., Kim E.S., Hong W.K. Chemoprevention of cancer. CA Cancer J Clin 2004, 54:150-180.
5. Liu R.H. Health benefits of fruit and vegetables are from additive and synergistic combinations of phytochemicals. Am J Clin Nutr 2003, 78(3):517S-520S.
6. Surh Y.J. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003, 3:768-780.
7. Davidson P.G., Touger-Decker R. Chemopreventive role of fruits and vegetables in oropharyngeal cancer. Nutr Clin Prac 2009, 24:250-260.
8. Aggarwal B.B., Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006, 71:1397-1421.
9. Surh Y.J., Na H.K. NF-κB and Nrf2 as prime molecular targets for chemoprevention and cytoprotection with anti-inflammatory and antioxidant phytochemicals. Genes Nutr 2008, 2(4):313-317.
10. Sarkar F.H., Li Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 2006, 66:3347-3350.
11. Tannock I.F., Osoba D., Stockler M.R., Ernst D.S., Neville A.J., Moore M.J., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996, 14(6):1756-1764.
12. Lev-Ari S., Vexler A., Starr A., Ashkenazy-Voghera M., Greif J., Aderka D., et al. Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Invest 2007, 25:411-418.
13. Fahey J.W., Talalay P. Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. Food Chem Toxicol 1999, 37:973-979.
14. Zhang Y., Tang L. Discovery and development of sulforaphane as a cancer chemopreventive phytochemical. Acta Pharmacol Sin 2007, 28(9):1343-1354.
15. Myzak M.C., Dashwood R.H. Chemoprotection by sulforaphane: keep one eye beyond keap1. Cancer Lett 2006, 233:208-218.
16. Brooks J.D., Paton V.G., Vidanes G. Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. Cancer Epidemiol Biomarkers Prev 2001, 10:949-954.
17. Herman-Antosiewicz A., Xiao H., Lew K.L., Singh S.V. Induction of p21 protein protects against sulforaphane-induced mitotic arrest in LnCap human prostate cancer cell line. Mol Cancer Ther 2007, 6:1673-1681.
18. Cho S.D., Li G., Hu H., Jiang C., Kang K.S., Lee Y.S., et al. Involvement of c-jun n-terminal kinase in g2/m arrest and caspase-mediated apoptosis induced by sulforaphane in DU145 prostate cancer cells. Nutr Cancer 2005, 52:213-224.
19. Parnaud G., Li P., Cassar G., Rouimi P., Tulliez J., Combaret L., et al. Mechanism of sulforaphane-induced cell cycle arrest and apoptosis in human colon cancer cells. Nutr Cancer 2004, 48:198-206.
20. Gamet-Payrastre L., Li P., Lumeau S., Cassar G., Dupont M.-A., Chevolleau S., et al. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res 2000, 60:1426-1433.
21. Mutch D.G., Bloss J.D. Gemcitabine in cervical cancer. Gynecol Oncol 2003, 90:8-15.
22. Chufal K.S., Rastogi M., Srivastava M., Pant M.C., Bhatt M.L.B., Srivastava K. Concurrent chemoradiotherapy for locally advanced cervical cancer using gemcitabine: nonrandomized comparison of three sequential protocols. Cancer Therapy 2007, 5:43-54.
23. Sharma C., Ahmed T., Sasidharan S., Ahmed M., Hussain A. Use of gemcitabine and ginger extract infusion may improve the efficiency of cervical cancer treatment. Afr J Biotechnol 2009, 8(24):7087-7093.
24. Sharma C., Kaur J., Shishodia S., Aggarwal B.B., Ralhan R. Curcumin down regulates smokeless tobacco-induced NF-κB activation and COX-2 expression in human oral premalignant and cancer cells. Toxicology 2006, 228:1-15.
25. Sharma R., Shukla N.K., Mathur M., Ralhan R. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer. Oncology 2004, 67:300-309.
26. Wang A.G., Kim S.U., Lee S.H., Kim S.K., Seo S.B., Yu D.Y., et al. Histone deacetylase 1 contributes to cell cycle and apoptosis. Biol Pharm Bull 2005, 28:1966-1970.
27. Bondesen B.A., Mills S.T., Kegley K.M., Pavlath G.K. The COX-2 pathway is essential during early stages of skeletal muscle regeneration. Am J Physiol Cell Physiol 2004, 287:475-483.
28. Salemi S., Rethage J., Wollina U., Michel B.A., Gay R.E., Gay S., et al. Detection of interleukin 1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia. J Rheumatol 2003, 30(1):146-150.
29. Adhami V.M., Aziz M.H., Mukhtar H., Ahmad N. Activation of prodeath Bcl-2 family proteins and mitochondrial apoptosis pathway by sanguinarine in immortalized human HaCaT keratinocytes. Clin Cancer Res 2003, 9(8):3176-3182.
30. Bold R.J., Chandra J., McConkey D.J. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol 1999, 6:279-285.
31. Julianne M., Davis Patrick M., Navolanic Caroline R., Weinstein-Oppenheimer, Steelman L.S., Hu W., et al. Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res 2003, 9:1161-1170.
32. Atchaneeyasakul L.O., Uiprasertkul M., Trinavarat A. Cyclooxygenase-2 expression in retinoblastoma: an immunohistochemical analysis. Curr Eye Res 2010, 35(3):242-247.
33. Hwang D., Scollard D., Byrne J., Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998, 90:455-460.
34. Reed J.R., Leon R.P., Hall M.K., Schwertfeger K.L. Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis. Breast Cancer Res 2009, 11(2):R21.
35. Gallicchio L., Visvanathan K., Burke A., Hoffman S.C., Helzlsouer K.J. Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. Int J Cancer 2007, 121:211-215.
36. Kwan M.L., Habel L.A., Slattery M.L., Caan B. NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control 2007, 18:613-620.
37. Barcelo S., Gardiner J.M., Gescher A., Chipman J.K. CYP2E1-mediated mechanism of anti-genotoxicity of the broccoli constituent sulforaphane. Carcinogenesis 1996, 17(2):277-282.
38. Gibbs A., Schwartzman J., Deng V., Alumkal J. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histonedeacetylase. Proc Natl Acad Sci 2009, 106(39):16663-16668.
39. Fimognari C., Nusse M., Berti F., Iori R., Cantelli-Forti G., Hrelia P. Cyclin D3 and p53 mediate sulforaphane induced cell cycle delay and apoptosis in non-transformed human T lymphocytes. Cell Mol Life Sci 2002, 59:2004-2012.
40. Pham N.A., Jacobberger J.W., Schimmer A.D., Cao P., Gronda M., Hedley D.W. The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice. Mol Cancer Ther 2004, 3:1239-1248.
41. Bryant C.S., Kumar S., Chamala S., Shah J., Pal J., Haider M., et al. Sulforaphane induces cell cycle arrest by protecting RB-E2F-1 complex in epithelial ovarian cancer cells. Mol Cancer 2010, 47.
42. Young S., Park G.I., Kim Y., Bae S.J., Yoo Y.H., Cho Y.H. Induction of apoptosis by isothiocyanate sulforaphane in human cervical carcinoma HeLa and hepatocarcinoma HepG2 cells through activation of caspase-3. Oncol Rep 2007, 18:181-187.
43. Ravindran J., Prasad S., Aggarwal B.B. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively?. AAPS J 2009, 11(3):495-510.
44. Veltkamp S.A., Pluim D., van Eijndhoven M.A., Bolijn M.J., Ong F.H., Govindarajan R., et al. New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine. Mol Cancer Ther 2008, 7(8):2415-2425.
45. Li Y., Ahmed F., Ali S., Philip P.A., Kucuk O., Sarkar F.H. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 2005, 65:6934-6942.
46. Banerjee S., Zhang Y., Ali S., Bhuiyan M., Wang Z., Chiao P.J., et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 2005, 65:9064-9072.
47. Li Y., Ellis K.L., Ali S., El-Rayes B.F., Nedeljkovic-Kurepa A., Kucuk O., et al. Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. Pancreas 2004, 28(4):e90-e95.
48. Bo Z., Zhong-Li S., Bing L., Xiao-Bo Y., Jie F., Hui-Min T. Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear factor-[kappa]B. Anti-Cancer Drugs 2010, 21(3):288-296.
49. Chan M.M., Fong D., Soprano K.J., Holmes W.F., Heverling H. Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. J Cell Physiol 2003, 194(1):63-70.
50. Fimognari C., Lenzi M., Sciuscio D., Cantelli-Forti G., Hrelia P. Combination of doxorubicin and sulforaphane for reversing doxorubicin-resistant phenotype in mouse fibroblasts with p53Ser220 mutation. Ann N Y Acad Sci 2007, 1095:62-69.
51. Ohnishi K., Ota I., Yane K., Takahashi A., Yuki K., Emoto M., et al. Glycerol as a chemical chaperone enhances radiation-induced apoptosis in anaplastic thyroid carcinoma cells. Mol Cancer 2002, 1:4.
52. Gamet-Payrastre L., Li P., Lumeau S., Cassar G., Dupont M.A., Chevolleau S., et al. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res 2000, 60:1426-1433.
53. Hernández P., Olivera P., Dueñas-Gonzalez A., Pérez-Pastenes M.A., Zárate A., Maldonado V., et al. Gemcitabine activity in cervical cancer cell lines. Cancer Chemother Pharmacol 2001, 48:488-492.
54. Yu D., Sekine-Suzuki E., Xue L., Fujimori A., Kubota N., Okayasu R. Chemopreventive agent sulforaphane enhances radiosensitivity in human tumor cells. Int J Cancer 2009, 125(September (5)):1205-1211.
55. Doudican N.A., Bowling B., Orlow S.J. Enhancement of arsenic trioxide cytotoxicity by dietary isothiocyanates in human leukemic cells via a reactive oxygen species-dependent mechanism. Leuk Res 2010, 34(2):229-234.
56. Frampton G.A., Lazcano E.A., Li H., Mohamad A., Demorrow S. Resveratrol enhances the sensitivity of cholangiocarcinoma to chemotherapeutic agents. Lab Invest 2010.
57. Pellecchia M., Reed J.C. Inhibition of anti-apoptotic Bcl-2 family proteins by natural polyphenols: new avenues for cancer chemoprevention and chemotherapy. Curr Pharm 2004, 10:1387-1398.
58. Haldar S., Chintapalli J., Croce C.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996, 56:1253-1255.
59. Sano H., Kawahito Y., Wilder R.L., Hashiramoto A., Mukai S., Asai K., et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1992, 555:3785-3789.
60. Kelley D.J., Mestre J.R., Subbaramaiah K., Sacks P.G., Schantz S.P., Tanabe T., et al. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis 1997, 18:795-799.
61. Hida T., Yatabe Y., Achiwa H., Muramatsu H., Kozaki K., Nakamura S., et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998, 58:3761-3764.
62. Taketo M.M. Cyclooxygenase-2 inhibitors in tumorigenesis. J Natl Cancer Inst 1998, 90:1609-1620.
63. Shan Y., Wu K., Wang W., Wang S., Lin N., Zhao R., et al. Sulforaphane down-regulates COX-2 expression by activating p38 and inhibiting NF-kappaB-DNA-binding activity in human bladder T24 cells. Int J Oncol 2009, 34(4):1129-1134.
64. Plummer S.M., Holloway K.A., Manson M.M., Munks R.J., Kaptein A., Farrow S., et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 1999, 18(44):6013-6020.
65. Woo K.J., Kwon T.K. Sulforaphane suppresses lipopolysaccharide-induced cyclooxygenase-2 (COX-2) expression through the modulation of multiple targets in COX-2 gene promoter. Int Immunopharmacol 2007, 7(13):1776-1783.
66. Park I.J., Lee Y.K., Hwang J.T., Kwon D.Y., Ha J., Park O.J. Green tea catechin controls apoptosis in colon cancer cells by attenuation of H2O2-stimulated COX-2 expression via the AMPK signaling pathway at low-dose H2O2. Ann N Y Acad Sci 2009, 1171:538-544.
67. Saijo Y., Tanaka M., Miki M., Usui K., Suzuki T., Maemondo M., et al. Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J Immunol 2002, 169(1):469-475.
68. Pantschenko A.G., Pushkar I., Anderson K.H., Wang Y., Miller L.J., Kurtzman S.H., et al. The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. Int J Oncol 2003, 23:269-284.
69. Estrov Z., Shishodia S., Faderl S., Harris D., Van Q., Kantarjian H.M., et al. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 2003, 102:987-995.
70. Moon Y., Glasgow W.C., Eling T.E. Curcumin suppresses interleukin 1β-mediated microsomal prostaglandin E synthase 1 by altering early growth response gene 1 and other signaling pathways. J Pharma Exp Ther 2005, 315:788-795.
71. Ritz S.A., Wan J., Diaz-Sanchez D. Sulforaphane-stimulated phase II enzyme induction inhibits cytokine production by airway epithelial cells stimulated with diesel extract. Am J Physiol Lung Cell Mol Physiol 2007, 292:L33-L39.
72. Shibata A., Nakagawa K., Yamanoi H., Tsuduki T., Sookwong P., Higuchi O., et al. Sulforaphane suppresses ultraviolet B-induced inflammation in HaCaT keratinocytes and HR-1 hairless mice. J Nutr Biochem 2009.
73. Cheung K.L., Khor T.O., Kong A.N. Synergistic effect of combination of phenethyl isothiocyanate and sulforaphane or curcumin and sulforaphane in the inhibition of inflammation. Pharm Res 2009, 26(1):224-231.